You are here: Industry Insights > Janssen

News List

Janssen acquires BeneVir Biopharm to advance immunotherapy regimens pharmatimes
May 04, 2018
Janssen has entered into a definitive agreement to acquire BeneVir Biopharm, a privately-held, biopharmaceutical company specializing in the development of oncolytic immunotherapies.
Janssen, Bristol-Myers Squibb Team Up to Develop Therapy biospace
April 19, 2018
Janssen Pharmaceuticals has teamed up with Bristol-Myers Squibb to drive BMS-986177, a Factor XIa (FXIa) inhibitor, into Phase II development for the study of secondary stroke prevention and major thrombotic conditions.
Janssen, Bristol-Myers Squibb Team Up to Develop Therapy biospace
April 18, 2018
Janssen Pharmaceuticals has teamed up with Bristol-Myers Squibb to drive BMS-986177, a Factor XIa (FXIa) inhibitor, into Phase II development for the study of secondary stroke prevention and major thrombotic conditions.
Janssen’s urothelial cancer drug gets breakthrough therapy designation pharmaceutical-technology
March 19, 2018
The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to Janssen Pharmaceutical’s erdafitinib for the treatment of patients with urothelial cancer.
Next Generation Biologics, Janssen's Tremfya, Eli Lilly's Taltz, and Novartis' Cosentyx, Raising the biospace
March 09, 2018
The past three years have brought with them a flurry of branded biologic approvals in dermatology, including four biologics for psoriasis alone
Janssen Forges Global Pact With Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy biospace
December 25, 2017
Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy
Genmab Achieves $20M Janssen Milestone contractpharma
December 01, 2017
The daratumumab collaboration progress is based on a study of the drug in a disease other than multiple myeloma
Janssen supports first-of-its-kind Asia Pacific Prostate Cancer- Patient Coalition to improve patien biospectrumasia
December 01, 2017
Prostate Cancer remains a low priority on the healthcare agendas of most Asian Countries
Janssen launches Tremfya in UK to treat psoriasis pharmaceufical-technology
November 27, 2017
Janssen has announced the availability of Tremfya (guselkumab) in the UK for adults with moderate-to-severe plaque psoriasis.
UK launch for Janssen’s novel psoriasis biologic Tremfya pharmatimes
November 27, 2017
Janssen has announced the launch of Tremfya in the UK for adults with moderate to severe plaque psoriasis, following a green light from European regulators

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page